Highlights | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Views 2,219
Citations 0
In This Issue of JAMA Dermatology
September 2014


JAMA Dermatol. 2014;150(9):921. doi:10.1001/jamadermatol.2013.6555

Cost control in health care requires a focus on value, or the quality of health outcomes for resources used. Hidradenitis suppurativa (HS) is a disease that lacks coordination of care, defined outcomes, and an understanding of costs. Anecdotally, treatments do not deliver on value. In this cohort cost-identification study, Kirby et al demonstrate that HS affects a younger, predominantly female population who more frequently use high-cost settings such as the emergency department and inpatient care. Educational interventions for patients with HS and nondermatologists may reduce unnecessary high-cost care, and defining meaningful outcome measures for patients may improve the value of health care for patients.